CSIMarket
 


Reviva Pharmaceuticals Holdings Inc   (RVPH)
Other Ticker:  
 

Reviva Pharmaceuticals Holdings Inc 's Quick Ratio

RVPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 0.9 a new company low.

Within Major Pharmaceutical Preparations industry 341 other companies have achieved higher Quick Ratio than Reviva Pharmaceuticals Holdings Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 748 to 1582.

Explain Quick Ratio?
How much Cash & cash equivalents RVPH´s has?
What are RVPH´s Current Liabilities?


RVPH Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 134.3 % 12.44 % 147.44 % 590.81 % 457.96 %
Y / Y Cash & cash equivalent Change -78.56 % -42.58 % -51.94 % -37.62 % -30.75 %
Quick Ratio MRQ 0.9 3.88 3.19 5.26 9.88
RVPH's Total Ranking # 1582 # 748 # 947 # 664 # 429
Seq. Current Liabilities Change 91.62 % -18.63 % 0.22 % 49.94 % -8.05 %
Seq. Cash & cash equivalent Change -55.41 % -0.92 % -39.22 % -20.15 % 19.42 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 342
Healthcare Sector # 645
Overall Market # 1582


Quick Ratio Statistics
High Average Low
290.51 35.51 0.9
(Aug 31 2018)   (Sep 30 2023)




Financial Statements
Reviva Pharmaceuticals Holdings Inc 's Current Liabilities $ 6 Millions Visit RVPH's Balance sheet
Reviva Pharmaceuticals Holdings Inc 's Cash & cash equivalent $ 5 Millions Visit RVPH's Balance sheet
Source of RVPH's Sales Visit RVPH's Sales by Geography


Cumulative Reviva Pharmaceuticals Holdings Inc 's Quick Ratio

RVPH's Quick Ratio for the trailling 12 Months

RVPH Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 134.3 % 12.44 % 147.44 % 590.81 % 457.96 %
Y / Y Cash & cash equivalent TTM Growth -78.56 % -42.58 % -51.94 % -37.62 % -30.75 %
Quick Ratio TTM 2.98 5.23 6.06 8.59 14
Total Ranking TTM # 1478 # 609 # 747 # 3348 # 490
Seq. Current Liabilities TTM Growth 91.62 % -18.63 % 0.22 % 49.94 % -8.05 %
Seq. Cash & cash equivalent TTM Growth -55.41 % -0.92 % -39.22 % -20.15 % 19.42 %


On the trailing twelve months basis Due to jump in Current Liabilities in the III Quarter 2023 to $5.50 millions, cumulative Quick Ratio decreased to 2.98 below the Reviva Pharmaceuticals Holdings Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 385 other companies have achieved higher Quick Ratio than Reviva Pharmaceuticals Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 609 to 1478.

Explain Quick Ratio?
How much Cash & cash equivalents RVPH´s has?
What are RVPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 386
Healthcare Sector # 712
Within the Market # 1478


trailing twelve months Quick Ratio Statistics
High Average Low
18.74 7.62 1.32
(Dec 31 2021)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Apellis Pharmaceuticals Inc   2.44 $ 452.414  Millions$ 185.630  Millions
Vyne Therapeutics Inc   2.40 $ 15.502  Millions$ 6.449  Millions
Beigene ltd   2.40 $ 3,078.884  Millions$ 1,283.297  Millions
Vincerx Pharma Inc   2.35 $ 20.802  Millions$ 8.846  Millions
Madrigal Pharmaceuticals Inc   2.34 $ 232.351  Millions$ 99.152  Millions
Siga Technologies Inc  2.31 $ 71.114  Millions$ 30.745  Millions
Insmed Inc  2.30 $ 785.951  Millions$ 341.213  Millions
Bioxcel Therapeutics Inc   2.28 $ 89.961  Millions$ 39.408  Millions
Galera Therapeutics Inc   2.25 $ 28.364  Millions$ 12.630  Millions
Precigen Inc   2.24 $ 73.755  Millions$ 32.875  Millions
Hutchmed china Limited  2.20 $ 886.336  Millions$ 403.027  Millions
Iterum Therapeutics Plc  2.19 $ 35.892  Millions$ 16.396  Millions
Acurx Pharmaceuticals inc   2.19 $ 7.052  Millions$ 3.223  Millions
Seres Therapeutics Inc   2.14 $ 169.912  Millions$ 79.225  Millions
Eton Pharmaceuticals Inc   2.12 $ 22.070  Millions$ 10.393  Millions
Omeros Corp  2.11 $ 310.310  Millions$ 147.176  Millions
Catalyst Pharmaceuticals Inc   2.09 $ 120.971  Millions$ 57.806  Millions
Hcw Biologics Inc   2.07 $ 11.221  Millions$ 5.417  Millions
Renovorx Inc   2.01 $ 3.226  Millions$ 1.605  Millions
Vaxxinity Inc   1.97 $ 42.519  Millions$ 21.561  Millions
Galectin Therapeutics Inc   1.94 $ 20.362  Millions$ 10.522  Millions
Conduit Pharmaceuticals Inc   1.88 $ 8.644  Millions$ 4.603  Millions
Geovax Labs Inc   1.79 $ 12.687  Millions$ 7.082  Millions
Alkermes Plc   1.77 $ 889.150  Millions$ 503.107  Millions
Tempest Therapeutics Inc   1.76 $ 11.118  Millions$ 6.305  Millions
Avidity Biosciences Inc   1.76 $ 85.650  Millions$ 48.716  Millions
Endo International Plc  1.76 $ 991.244  Millions$ 564.632  Millions
Macrogenics Inc   1.75 $ 89.898  Millions$ 51.291  Millions
Summit Therapeutics Inc   1.75 $ 198.945  Millions$ 113.742  Millions
Ultragenyx Pharmaceutical Inc   1.74 $ 442.094  Millions$ 253.978  Millions

Date modified: 2023-11-16T13:31:07+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com